Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

On January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS...

  • 1616448245106094092 Profile photo of Madelyn

    It's great to see a drug initially developed for use against HER2+ breast cancer be extended for use in HER2+ colorectal cancer. A new option for some patients with stage 4 colon cancer, @FDAOncology https://t.co/ijDabkB6wj #crcsm #onctwitter #biomarkers #coloncancer #tucatinib - view on twitter

Many patients diagnosed with colon cancer require surgery as part of their treatment. Yi-Qian Nancy You, M.D., answers common questions about colon cancer surgery...

Mashup Score:1

lww.com

Wolters Kluwer Health - 1 week

Mashup Score:1

JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers:...

A major clinical study raised questions about one of the most celebrated cancer-screening procedures available, but a close look at the data tells a...

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to...

A recent study has found evidence linking exposure to salmonella to an increased risk of colon cancer. Salmonella is a common bacterial disease...

PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation. METHODS Patients with radiologically...

Intercellular communication plays a critical role in the ever-evolving landscape of invasive cancers. Recent studies have elucidated the potential role of tunneling nanotubes (TNTs)...

In the observational GALAXY arm of the CIRCULATE-Japan study, among 1,049 patients with stage II–IV colorectal cancer, those with presence of circulating tumor DNA...

Consider it now ‘an option’ for locally advanced disease, editorialists...